Although the directives to limit publicly available healthcare data and cut federal funding for medical research have been temporarily blocked by federal judges, providers face uncertainty as they await final rulings.
Trump administration healthcare executive orders hit snags in court Read More »
Este es una de las sombrías conclusiones a las que se ha llegado en un nuevo estudio. Este estudio es obra de un equipo dirigido desde la LSHTM (London School of Hygiene & Tropical Medicine) del Reino Unido y en el que participa la Estación Biológica de Doñan …
The pharma giant inked its third T cell engager deal of 2025 Wednesday—this time with Xilio Therapeutics for tumor-activated immunotherapies.
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B Read More »
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s disease. With patients now hitting the 18-month mark of treatment, the conversation is finally shifting to efficacy.
With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works Read More »
Year-over-year BioSpace data shows there were fewer job postings live on the website in the fourth quarter of 2024, and the decrease was higher than the third quarter’s drop.
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued Read More »
Una investigación reciente ha revelado la existencia de biofluorescencia en muchas de las especies conocidas de aves del paraíso, que viven en zonas del mundo que incluyen territorios de Australia, Indonesia y Nueva Guinea. El estudio es obra de Rene Martin, de la Universidad …
Unos científicos han conseguido reconectar, en una rata a modo de prueba de lo que quizá podría hacerse en humanos, una médula espinal totalmente seccionada a nivel torácico. El logro ha sido posible gracias a una espuma en tres dimensiones creada con óxido …
Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.
How Trump’s trade fight could impact the medtech industry Read More »
Researchers suggested that policymakers encourage reinvestment of capital into patient care and limit share buybacks based on the findings.
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment Read More »
